Psychedelics such as psilocybin have been shown to have persistent antidepressant effects, but with considerable individual variability in optimal dosing. Intravenous (IV) dosing is rapid onset and quickly titrated, possibly preceded by an anxiolytic for patient comfort. We explored the viability of IV psilocin with and without preadministration of lorazepam for possible future inpatient therapeutic utility.
Methods:
Male Wistar-Kyoto rats were given saline (S), psilocin (P), or psilocin and lorazepam (P+L). Saline was given intraperitoneally (IP), psilocin was given IV to a second group, and lorazepam was given IP, then psilocin was given IV 30 min later to a final group. Rats were tested in the forced swim test (FST) 3 and 14 weeks after injection.
Results:
P rats were more active than S rats at both time points. P + L rats were more active in the FST than S rats at 3, but not 14, weeks. P + L rats were less active than P rats at 14 weeks, and less active than themselves at 3 weeks. S rats' behavior was not different at 3 and 14 weeks. Similarly, P rats behaved the same at both time points.
Conclusions:
IV psilocin persistently decreased immobility in the FST, but lorazepam reduced psilocin's antidepressant-like efficacy and longevity.
Get full access to this article
View all access options for this article.
References
1.
Carhart-HarrisRL, BolstridgeM, RuckerJ, et al.Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry, 2016; 3(7):619–627; doi: 10.1016/S2215-0366(16)30065-7
2.
Carhart-HarrisRL, RosemanL, BolstridgeM, et al.Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep, 2017; 7(1):13187; doi: 10.1038/s41598-017-13282-7
GriffithsRR, JohnsonMW, CarducciMA, et al.Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol, 2016; 30(12):1181–1197; doi: 10.1177/0269881116675513
5.
Jiménez-GarridoDF, Gómez-SousaM, OnaG, et al.Effects of ayahuasca on mental health and quality of life in naïve users: A longitudinal and cross-sectional study combination. Sci Rep, 2020; 10(1):1–12; doi: 10.1038/s41598-020-61169-x
6.
Palhano-FontesF, BarretoD, OniasH, et al.A randomized placebo-controlled trial on the antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression. bioRxiv, 2017; 103531; doi: 10.1101/103531
7.
CameronLP, BensonCJ, DunlapLE, et al.Effects of N,N-dimethyltryptamine on rat behaviors relevant to anxiety and depression. ACS Chem Neurosci, 2018; doi: 10.1021/acschemneuro.8b00134
8.
CameronLP, BensonCJ, DeFeliceBC, et al.Chronic, intermittent microdoses of the psychedelic N,N-dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents. ACS Chem Neurosci, 2019; 10(7):3261–3270; doi: 10.1021/acschemneuro.8b00692
9.
HibickeM, LandryAN, KramerHM, et al.Psychedelics, but not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression. ACS Chem Neurosci, 2020; doi: 10.1021/acschemneuro.9b00493
10.
HibickeM, NicholsCD. Validation of the forced swim test in Drosophila, and its use to demonstrate psilocybin has long-lasting antidepressant-like effects in flies. Sci Rep, 2022; 12(1):10019; doi: 10.1038/s41598-022-14165-2
11.
LahmameA, del ArcoC, PazosA, et al.Are Wistar-Kyoto rats a genetic animal model of depression resistant to antidepressants?. Eur J Pharmacol, 1997; 337(2):115–123; doi: 10.1016/S0014-2999(97)01276-4
12.
MillardSJ, Weston-GreenK, NewellKA. The Wistar-Kyoto rat model of endogenous depression: A tool for exploring treatment resistance with an urgent need to focus on sex differences. Prog Neuro-Psychopharmacol Biol Psychiatry, 2020; 109908; doi: 10.1016/j.pnpbp.2020.109908
13.
AloweidiA, Abu-HalawehS, AlmustafaM, et al.Preoperative anxiety among adult patients undergoing elective surgeries at a tertiary teaching hospital: A cross-sectional study during the era of COVID-19 vaccination. Healthcare (Basel), 2022; 10(3):515; doi: 10.3390/healthcare10030515
14.
JiwanmallM, JiwanmallSA, WilliamsA, et al.Preoperative anxiety in adult patients undergoing day care surgery: Prevalence and associated factors. Indian J Psychol Med, 2020; 42(1):87–92; doi: 10.4103/IJPSYM.IJPSYM_180_19
15.
BhattacharyaSK, SatyanKS, ChakrabartiA. Anxiogenic action of caffeine: An experimental study in rats. J Psychopharmacol, 1997; 11(3):219–224; doi: 10.1177/026988119701100304
16.
ShermanAD, AllersGL, PettyF, et al.A neuropharmacologically-relevant animal model of depression. Neuropharmacology, 1979; 18(11):891–893; doi: 10.1016/0028-3908(79)90087-X
17.
Anonymous. Effect of GABAergic drugs on motor impairment from ethanol, barbital and lorazepam in rat lines selected for differential sensitivity to ethanol. Pharmacol Biochem Behav, 1989; 34(2):399–404; doi: 10.1016/0091-3057(89)90333-X
18.
FinsetA, AnderssonS. Coping strategies in patients with acquired brain injury: Relationships between coping, apathy, depression and lesion location. Brain Inj, 2000; 14(10):887–905; doi: 10.1080/026990500445718
19.
Gutiérrez-ZotesA, LabadJ, Martín-SantosR, et al.Coping strategies and postpartum depressive symptoms: A structural equation modelling approach. Eur Psychiatry, 2015; 30(6):701–708; doi: 10.1016/j.eurpsy.2015.06.001
20.
MahmoudJSR, “Topsy”SR, HallLA, et al.The relationship among young adult college students' depression, anxiety, stress, demographics, life satisfaction, and coping styles. Issues Ment Health Nurs, 2012; 33(3):149–156; doi: 10.3109/01612840.2011.632708
21.
TsujimotoE, TsujiiN, MikawaW, et al.Discrepancies between self- and observer-rated depression severities in patients with major depressive disorder associated with frequent emotion-oriented coping responses and hopelessness. Neuropsychiatr Dis Treat, 2018; 14:2331–2336; doi: 10.2147/NDT.S175973
22.
UeharaT, SakadoK, SakadoM, et al.Relationship between stress coping and personality in patients with major depressive disorder. PPS, 1999; 68(1):26–30; doi: 10.1159/000012307
23.
CommonsKG, CholaniansAB, BabbJA, et al.The rodent forced swim test measures stress-coping strategy, not depression-like behavior. ACS Chem Neurosci, 2017; 8(5):955–960; doi: 10.1021/acschemneuro.7b00042
24.
KentM, BardiM, HazelgroveA, et al.Profiling Coping Strategies in Male and Female Rats: Potential neurobehavioral markers of increased resilience to depressive symptoms. Horm Behav, 2017; 95:33–43; doi: 10.1016/j.yhbeh.2017.07.011
25.
OnoY, LinH-C, TzenK-Y, et al.Active coping with stress suppresses glucose metabolism in the rat hypothalamus. Stress, 2012; 15(2):207–217; doi: 10.3109/10253890.2011.614296
26.
PorsoltRD, Le PichonM, JalfreM. Depression: A new animal model sensitive to antidepressant treatments. Nature, 1977; 266(5604):730–732; doi: 10.1038/266730a0
27.
CryanJF, ValentinoRJ, LuckiI. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev, 2005; 29(4–5):547–569; doi: 10.1016/j.neubiorev.2005.03.008
SlatteryDA, CryanJF. Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat Protoc, 2012; 7(6):1009–1014; doi: 10.1038/nprot.2012.044
